1. Welcome to Graduate School of Biomedical Sciences (GSBS)
at the U T Health Science Center at Houston
and M D Anderson Cancer Center
August 20, 2018
Mien-Chie Hung, Ph.D.
Vice President for Basic Research
Professor and Chair
Department of Molecular and Cellular Oncology

2. You come to the best place
Congratulations
You come to the best place
to do cancer research &
for graduate studies

3. Cell Biology Physiology Cancer Biology NRC S ranking in 2010,
122 programs

4. Since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals, and it has ranked first 14 times in the last 17 years.

5. It has ranked first 14 times in the last 17 years.
MD Anderson remains the the leading hospital in the US.
It has ranked first 14 times in the last 17 years.
GSBS partners with MD Anderson in cancer research.

6. Training Opportunities
Scientific Thinking and Bench Skills
Writing and Oral Presentation Training
Retreats & Social Event to meet the leaders in academy (Noble Laureates, Members of National Academy of Sciences), industry, patent law and others ,
Learn how to be successful

7. Research Achievements & Awards
High impact publications
National and State Awards, NIH F31, DOD
UT system and GSBS prestigious awards and scholarship

8. PTEN loss induced by astrocyte-derived exosomal microRNA primes brain metastasis outgrowth via cross-talk between tumor cells and brain metastatic microenvironment.
L. Zhang, S. Zhang, …, D. Yu, Nature, 11/2015

9. A common pathway shared between cancer and diabetes
Breast Cancer
Fat cells
Energy
Diabetes
Dung-Fang Lee
2004 Cell
2007 Cell
2009 Mol Cell
UT HSC
CPRIT awardee

10. The University of Texas System Regents’ Outstanding Teaching Award
Mien-Chie Hung

11. The University of Texas System Regents’ Outstanding Teaching Award
Dihua Yu
Naoto Ueno
Mien-Chie Hung
青出於藍而勝於藍

12. GSBS alumni in industry, a few examples
Jing Shan Jennifer Hu
Vice President and Head of Innovation Center China
Global Drug Discovery
Bayer Health Pharmaceuticals
Kerry Russell
Vice President, Clinical Development at resTORbio
2004 Cell, cited: 550, 2007 Cell, cited: 297
2005 Science, cited: 231

13. Institute for Applied Cancer Science Institute for Basic Science
Research Opportunities
Institute for Applied Cancer Science
Institute for Basic Science
Institute for Cancer Care Innovation
Duncan Family Institute
McCombs Institute
Zayed Institute for Personalized Cancer Therapy

14. Institute for Applied Sciences (IACS)
VP, Therapeutic Discovery and Head of Drug Discovery: Phil Jones, PhD Co-leader, Moon Shot Programs and IACS & SVP, Therapeutic Discovery Giulio Draetta, MD, PhD, Mission To apply scientific knowledge of mechanisms driving tumor development and maintenance into the development of impactful small molecule cancer therapies.

15. Institute of Basic Science
Research
Institute of Basic Science
Director: Mien-Chie Hung, PhD.
Biological Pathways
Cancer Epigenetics
Environmental and Molecular Carcinogenesis
Genetics and Genomics
Inflammation and Cancer
Stem Cell and Developmental Biology

16. 2018 Albany Medical Center Prize in Medicine and Biomedical Research
James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center
Carl June, M.D., Perelman School of Medicine, University of Pennsylvania
Steven A. Rosenberg, M.D., Ph.D., National Cancer Institute, National Institutes of Health
$500,000, they are being recognized for their contributions to research that established immunotherapy as a revolutionary and effective method to treat cancer and other diseases

17. Targeting PD-L1 glycosylation enhances anti-tumor immunityB C D d E e
Li, Lim, et al, Cancer Cell, 2018, Feb
StCube,Inc

18. 2018 Tang Prize in Biopharmaceutical Science
Brian Druker, The Knight Cancer Institute, Oregon Health & Science University
Tony Hunter, The Salk Institute
John Mendelsohn, The University of Texas MD Anderson Cancer Center
$1.33 mils

19. Lung cancer is the leading cause of cancer death in both man and women for more than 6 years.

20. Lee, et al, Cancer Cell 2018 Sep.
PKCδ serves as a common therapeutic target for resistance of EGFR kinase inhibitors and an option for treatment.
Tumor size (mm3)
H1975 tumor (T790M+)
Control
AZD9291
Sotra
AZD+Sotra
Days after treatment
TM0204 PDX (T790M+)
EGFR activation-mutation occurs in about 50% Asia
and 15% Caucasian NSCLC cancer population.
EGFR kinase inhibitors suppress tumor development and
patients survive for a couple of years,
but eventually tumors develop with multiple
resistant mechanisms leaving no effective option for patients.
Lee, et al, Cancer Cell 2018 Sep.

21. Heart